Nick Srikanth

Nick is the Head of Strategy at Senda Biosciences. He is responsible for corporate and portfolio strategy, business operations and external communications.

Prior to joining Senda, Nick was at The Boston Consulting Group (BCG), where he advised Biopharma clients on a range of strategic issues (focusing in particular on long term strategy, launch planning, and lifecycle management). He has also worked at Novartis and GSK in a variety of commercial and strategic roles across the vaccines and consumer healthcare businesses. His roles included: leading the long-term strategy and lifecycle management planning for Shingrix (GSK’s blockbuster shingles vaccine); running the TUMS business in the US (the #1 product in the antacid category); and serving as Chief of Staff to the CEO of GSK Consumer Healthcare. Nick began his career as an investment banking analyst with Deutsche Bank.

Nick holds an MBA from the Tuck School of Business at Dartmouth, and a BS in Economics and Mathematical Methods in the Social Sciences from Northwestern University.